A novel semi-manufactured chicken surimi product with nutritional benefits could be developed by fortification with fish or flaxseed oil.

Activated carbon nanofibers (ACFs) with high specific surface area, excellent conductivity, and narrow pore‐size distribution, are regarded as a promising electrode material for high‐performance supercapacitors (SCs). Herein, a facile route to synthesize large‐scale amorphous CF (a‐CF) using catalytic pyrolysis of acetylene (C2H2) at 260 °C over copper catalysts is reported. The conversion rate of acetylene into a‐CF is estimated as high as 72.05 wt%. Subsequently, the as‐prepared a‐CF is transformed into ACFs by potassium hydroxide (KOH) at 800 °C with high specific surface area and porous structures. Moreover, nitrogen‐doped ACFs are conducted in the activation step through a physical mixing of a‐CF/KOH/melamine with various ratios. For SCs, the as‐prepared N‐ACFs display excellent specific capacitance and cycle stability. In the three‐electrode system, the N‐ACF (CF‐03) demonstrates a specific capacitance value of 227 F g−1 at 0.5 A g−1, and shows a 94% capacitance retention after a long cycle (10 000 cycles) at 2 A g−1. Moreover, the CF‐03‐based two‐electrode SC demonstrates a high energy density of 14.30 Wh kg−1 and a high power density of 79.88 W kg−1 in 1 m Na2SO4 electrolyte. Herein, a simple and promising way to prepare large‐scale a‐CF, ACF, and N‐doped ACFs is demonstrated.

No abstract

No abstract

Objective:The KEYNOTE-590 trial showed that individuals with advanced esophageal cancer who received Pembrolizumab in combination with chemotherapy as a first-line regimen achieved a significant extension of survival. However, this treatment option increases the financial burden on patients and the economic benefits remain to be further evaluated.Methods: A Markov model was used to simulate 10-year survival of patients with esophageal cancer from the perspective of United States (US) Medicare payers. We evaluated the economics of Pembrolizumab plus chemotherapy in the PD-L1 positive score (CPS ≥10) and any PD-L1 expression groups, respectively. We estimated total costs, quality-adjusted life years (QALYs), and calculated incremental cost effectiveness ratios (ICERs). Sensitivity analyses were conducted to explore the impact of uncertainties on the results. Subgroup analysis was also performed. Results:The analysis results showed that the ICER for pembrolizumab plus chemotherapy versus chemotherapy alone was $293,513.